Induct AS and AstraZeneca Accelerate Strategic Collaboration for Severe Asthma Care

Induct AS has announced that AstraZeneca has decided to accelerate the initiation of commercial discussions related to their strategic collaboration, marking a significant milestone for the company. The discussions aim to develop a concrete framework for the rollout of Induct's care pathway for severe asthma in the UK healthcare market, with the first digital meetings scheduled to take place before the summer of 2025 and an in-person meeting in England in July.

Key Takeaways:

• AstraZeneca has accelerated the initiation of commercial discussions with Induct AS, indicating a strong interest in the company's care pathway for severe asthma.
• The collaboration will cover subscription-based pricing models and strategy for the national rollout of the severe asthma program in England.
• AstraZeneca now wishes to expand the collaboration to include other care pathways where Induct can contribute to increased value for healthcare services and patients.
• Induct's CEO, Synnove Jacobsen, expressed enthusiasm for the discussions, highlighting the relevance and potential of their solution.
• Chairman of the Board at Induct, Karl-Anders Gronland, confirmed the strong trust between the parties, and the collaboration's entry into a new, more concrete phase reflects this.

Statistics:

• Induct's care pathway for severe asthma will be rolled out in the UK healthcare market.
• The first digital meetings between AstraZeneca and Induct AS will occur before the summer of 2025.
• An in-person meeting in England is scheduled for July, following the digital meetings.
• AstraZeneca will cover subscription-based pricing models and strategy for the national rollout of the severe asthma program in England.

Sources:

• Induct AS news release, Oslo.